An Aged Microenvironment Increases CAR T Cell Cytotoxicity but Impairs Therapeutic Efficacy
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Cancer disproportionately affects the elderly, who are often less able to tolerate traditional cytotoxic therapies, and may benefit from T cell–based immunotherapies. However, studies evaluating the efficacy of T cell immunotherapy in aged mice are limited and yield inconsistent results, while clinical data are largely retrospective.
Methods
Here, we used a murine model of Chimeric Antigen Receptor (CAR) T cell therapy to investigate how aging influences efficacy, from CAR T cell production to in vivo anti-tumor activity.
Results
We found that aging reduced CAR T cell production yields and altered their phenotype and function. Aged CAR T cells were predominantly effector memory CD4⁺ T cells, whereas young CAR T cells were primarily central memory CD8⁺ T cells. Functionally, aged CAR T cells exhibited non-specific cytotoxicity, driven by constitutive degranulation and elevated granzyme B secretion independent of CAR expression. This phenotype was induced by the aged microenvironment, as young T cells transferred into aged hosts adopted similar behavior. In vivo, young CAR T cells efficiently reduced tumor burden in young leukemia-bearing hosts, but were not effective in aged hosts, where the aged microenvironment impaired CAR T cell persistence.
Conclusion
These findings indicate that aging impacts CAR T cell therapy at multiple levels, from manufacturing to therapeutic efficacy, highlighting the need to design tailored immunotherapies for elderly patients.
